PharmEasy valuation, funding and investors

PharmEasy works in digital healthcare platform services, based in Mumbai, India. Founded in 2015, it has about 3,980 employees.

Debt

VALUATION · TODAY

$810M −2% after Growth

Range $259M – $932M · Grade C

TODAY

+12 MO

$1.00B

$2.00B

$3.00B

$4.00B

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

Series A $5.00M

Series B $17.0M

Series C $50.0M

Growth $220M

Series E $350M

Growth $216M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY3,978 employees

+0%6m growth

+1%1y growth

+8%2y growth

2,500

5,000

Data from Jan 2021

TODAY

Predicted in 1 yr $791M −2% vs today

Predicted next raise $82.6M if a round comes

Winding-down probability 0%

Last round: Growth · $216M · Apr 2024
Valuation at last round: $710M
Headcount: 3,978 · flat
Grade: C
Founded: 2015

How VCMC values companies →

PharmEasy valuation today

VCMC values PharmEasy at $810M today, with a range of $259M to $932M and a grade of C. The valuation starts from its last funding round, a growth round in Apr 2024.

Valuation by date (148 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

PharmEasy: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2015	$2.03M	$0.74M – $5.59M	$2.13M (+5%)	before first round	–	unknown	D	0%
1 Feb 2015	$2.04M	$0.74M – $5.61M	$2.14M (+5%)	before first round	–	unknown	D	0%
1 Mar 2015	$2.05M	$0.75M – $5.63M	$2.15M (+5%)	before first round	–	unknown	D	0%
1 Apr 2015	$2.06M	$0.75M – $5.65M	$2.16M (+5%)	before first round	–	unknown	D	0%
1 May 2015	$2.07M	$0.75M – $5.67M	$2.16M (+5%)	before first round	–	unknown	D	0%
1 Jun 2015	$2.07M	$0.75M – $5.70M	$2.17M (+5%)	before first round	–	unknown	D	0%
1 Jul 2015	$2.08M	$0.76M – $5.72M	$2.18M (+5%)	before first round	–	unknown	D	0%
1 Aug 2015	$2.09M	$0.76M – $5.74M	$2.24M (+7%)	before first round	–	unknown	D	0%
1 Sep 2015	$2.10M	$0.76M – $5.76M	$2.30M (+10%)	before first round	–	unknown	D	0%
1 Oct 2015	$2.11M	$0.77M – $5.79M	$2.36M (+12%)	before first round	–	unknown	D	0%
1 Nov 2015	$2.11M	$0.77M – $5.81M	$2.42M (+15%)	before first round	–	unknown	D	0%
1 Dec 2015	$2.12M	$0.77M – $5.83M	$2.49M (+17%)	before first round	–	unknown	D	0%
1 Jan 2016	$24.2M	$15.9M – $66.2M	$43.5M (+80%)	after a round	–	unknown	C	0%
2 Jan 2016	$24.2M	$15.9M – $66.2M	$43.5M (+80%)	after a round	–	unknown	C	0%
1 Feb 2016	$25.4M	$15.9M – $66.2M	$43.5M (+71%)	after a round	–	unknown	C	0%
1 Mar 2016	$26.6M	$15.9M – $66.2M	$43.5M (+63%)	after a round	–	unknown	C	0%
1 Apr 2016	$28.0M	$15.9M – $66.2M	$43.5M (+55%)	after a round	–	unknown	C	0%
1 May 2016	$29.3M	$15.9M – $66.2M	$43.5M (+48%)	after a round	–	unknown	C	0%
1 Jun 2016	$30.8M	$15.9M – $66.2M	$43.5M (+41%)	after a round	–	unknown	C	0%
1 Jul 2016	$32.4M	$15.9M – $66.2M	$43.5M (+34%)	after a round	–	unknown	C	0%
1 Aug 2016	$34.0M	$15.9M – $66.2M	$43.5M (+28%)	after a round	–	unknown	C	0%
1 Sep 2016	$35.8M	$15.9M – $66.2M	$43.5M (+22%)	after a round	–	unknown	C	0%
1 Oct 2016	$37.5M	$15.9M – $66.2M	$43.5M (+16%)	after a round	–	unknown	C	0%
1 Nov 2016	$39.5M	$15.9M – $66.2M	$43.5M (+10%)	after a round	–	unknown	C	0%
1 Dec 2016	$41.4M	$15.9M – $66.2M	$43.5M (+5%)	after a round	–	unknown	C	0%
1 Jan 2017	$43.5M	$15.9M – $66.2M	$43.5M (0%)	after a round	–	unknown	C	0%
1 Feb 2017	$43.5M	$15.1M – $66.2M	$43.5M (0%)	after a round	–	unknown	C	0%
1 Mar 2017	$43.5M	$14.4M – $66.2M	$43.5M (0%)	after a round	–	unknown	C	0%
1 Apr 2017	$43.5M	$13.7M – $66.2M	$43.5M (0%)	after a round	–	unknown	C	0%
4 Apr 2017	$81.7M	$57.5M – $174M	$122M (+50%)	after a round	–	unknown	B	0%
1 May 2017	$84.1M	$57.5M – $174M	$122M (+45%)	after a round	–	unknown	B	0%
1 Jun 2017	$87.1M	$57.5M – $174M	$122M (+40%)	after a round	–	unknown	B	0%
1 Jul 2017	$90.0M	$57.5M – $174M	$122M (+36%)	after a round	–	unknown	B	0%
1 Aug 2017	$93.2M	$57.5M – $174M	$122M (+31%)	after a round	–	unknown	B	0%
1 Sep 2017	$96.4M	$57.5M – $174M	$122M (+27%)	after a round	–	unknown	B	0%
1 Oct 2017	$99.7M	$57.5M – $174M	$122M (+23%)	after a round	–	unknown	B	0%
1 Nov 2017	$103M	$57.5M – $174M	$122M (+19%)	after a round	–	unknown	B	0%
1 Dec 2017	$107M	$57.5M – $174M	$122M (+15%)	after a round	–	unknown	B	0%
1 Jan 2018	$110M	$57.5M – $174M	$122M (+11%)	after a round	–	unknown	B	0%
1 Feb 2018	$114M	$57.5M – $174M	$122M (+7%)	after a round	–	unknown	B	0%
1 Mar 2018	$118M	$57.5M – $174M	$122M (+4%)	after a round	–	unknown	B	0%
1 Apr 2018	$122M	$57.5M – $174M	$122M (0%)	after a round	–	unknown	B	0%
1 May 2018	$122M	$55.2M – $174M	$122M (0%)	after a round	–	unknown	B	0%
1 Jun 2018	$122M	$52.9M – $174M	$122M (0%)	after a round	–	unknown	B	0%
1 Jul 2018	$122M	$50.6M – $174M	$122M (0%)	after a round	–	unknown	C	0%
1 Aug 2018	$122M	$48.5M – $174M	$122M (0%)	after a round	–	unknown	C	0%
1 Sep 2018	$122M	$46.4M – $174M	$122M (0%)	after a round	–	unknown	C	0%
27 Sep 2018	$294M	$207M – $542M	$382M (+30%)	after a round	–	unknown	B	0%
1 Oct 2018	$295M	$207M – $542M	$382M (+30%)	after a round	–	unknown	B	0%
1 Nov 2018	$301M	$207M – $542M	$382M (+27%)	after a round	–	unknown	B	0%
1 Dec 2018	$308M	$207M – $542M	$382M (+24%)	after a round	–	unknown	B	0%
1 Jan 2019	$315M	$207M – $542M	$382M (+21%)	after a round	–	unknown	B	0%
1 Feb 2019	$322M	$207M – $542M	$382M (+19%)	after a round	–	unknown	B	0%
1 Mar 2019	$329M	$207M – $542M	$382M (+16%)	after a round	–	unknown	B	0%
1 Apr 2019	$336M	$207M – $542M	$382M (+14%)	after a round	–	unknown	B	0%
1 May 2019	$343M	$207M – $542M	$382M (+11%)	after a round	–	unknown	B	0%
1 Jun 2019	$351M	$207M – $542M	$382M (+9%)	after a round	–	unknown	B	0%
1 Jul 2019	$359M	$207M – $542M	$382M (+6%)	after a round	–	unknown	B	0%
1 Aug 2019	$367M	$207M – $542M	$382M (+4%)	after a round	–	unknown	B	0%
1 Sep 2019	$375M	$207M – $542M	$382M (+2%)	after a round	–	unknown	B	0%
1 Oct 2019	$382M	$206M – $542M	$382M (0%)	after a round	–	unknown	B	0%
1 Nov 2019	$382M	$196M – $542M	$382M (0%)	after a round	–	unknown	B	0%
28 Nov 2019	$1.2B	$866M – $1.9B	$1.4B (+10%)	after a round	–	unknown	B	0%
1 Dec 2019	$1.2B	$866M – $1.9B	$1.4B (+10%)	after a round	–	unknown	B	0%
1 Jan 2020	$1.2B	$866M – $1.9B	$1.4B (+9%)	after a round	–	unknown	B	0%
1 Feb 2020	$1.2B	$866M – $1.9B	$1.4B (+8%)	after a round	–	unknown	B	0%
1 Mar 2020	$1.3B	$866M – $1.9B	$1.4B (+7%)	after a round	–	unknown	B	0%
1 Apr 2020	$1.3B	$866M – $1.9B	$1.4B (+6%)	after a round	–	unknown	B	0%
1 May 2020	$1.3B	$866M – $1.9B	$1.4B (+6%)	after a round	–	unknown	B	0%
1 Jun 2020	$1.3B	$866M – $1.9B	$1.4B (+5%)	after a round	–	unknown	B	0%
1 Jul 2020	$1.3B	$866M – $1.9B	$1.4B (+4%)	after a round	–	unknown	B	0%
1 Aug 2020	$1.3B	$866M – $1.9B	$1.4B (+3%)	after a round	–	unknown	B	0%
1 Sep 2020	$1.3B	$866M – $1.9B	$1.4B (+2%)	after a round	–	unknown	B	0%
1 Oct 2020	$1.3B	$866M – $1.9B	$1.4B (+1%)	after a round	–	unknown	B	0%
1 Nov 2020	$1.3B	$866M – $1.9B	$1.4B (+1%)	after a round	–	unknown	B	0%
1 Dec 2020	$1.4B	$859M – $1.9B	$1.4B (0%)	after a round	–	unknown	B	0%
1 Jan 2021	$1.4B	$816M – $1.9B	$1.4B (0%)	after a round	740	unknown	B	0%
1 Feb 2021	$1.4B	$776M – $1.9B	$1.4B (0%)	after a round	740	unknown	B	0%
1 Mar 2021	$1.4B	$741M – $1.9B	$1.4B (0%)	after a round	740	unknown	B	0%
1 Apr 2021	$1.4B	$704M – $1.9B	$1.4B (0%)	after a round	740	unknown	B	0%
8 Apr 2021	$1.5B	$1.3B – $2.2B	$2.0B (+30%)	after a round	740	unknown	A	0%
1 May 2021	$1.5B	$1.3B – $2.2B	$2.0B (+28%)	after a round	740	unknown	A	0%
1 Jun 2021	$1.6B	$1.3B – $2.2B	$2.0B (+25%)	after a round	740	unknown	A	0%
1 Jul 2021	$1.6B	$1.3B – $2.2B	$2.0B (+22%)	after a round	740	unknown	A	0%
1 Aug 2021	$1.6B	$1.3B – $2.2B	$2.0B (+20%)	after a round	740	unknown	A	0%
1 Sep 2021	$1.7B	$1.3B – $2.2B	$2.0B (+17%)	after a round	740	unknown	A	0%
1 Oct 2021	$1.7B	$1.3B – $2.2B	$2.0B (+14%)	after a round	740	unknown	A	0%
1 Nov 2021	$1.7B	$1.3B – $2.2B	$2.0B (+12%)	after a round	740	unknown	A	0%
1 Dec 2021	$1.8B	$1.3B – $2.2B	$2.0B (+10%)	after a round	740	unknown	A	0%
1 Jan 2022	$1.8B	$1.3B – $2.2B	$2.0B (+7%)	after a round	740	unknown	A	0%
1 Feb 2022	$1.9B	$1.3B – $2.2B	$2.0B (+5%)	after a round	740	unknown	A	0%
1 Mar 2022	$1.9B	$1.3B – $2.2B	$2.0B (+3%)	after a round	740	unknown	A	0%
1 Apr 2022	$1.9B	$1.3B – $2.2B	$2.0B (0%)	after a round	740	unknown	A	0%
1 May 2022	$2.0B	$1.3B – $2.2B	$2.0B (0%)	after a round	740	unknown	A	0%
1 Jun 2022	$2.0B	$1.2B – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Jul 2022	$2.0B	$1.1B – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Aug 2022	$2.0B	$1.1B – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Sep 2022	$2.0B	$1.0B – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Oct 2022	$2.0B	$1.0B – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Nov 2022	$2.0B	$956M – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Dec 2022	$2.0B	$914M – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Jan 2023	$2.0B	$872M – $2.2B	$2.0B (0%)	after a round	740	unknown	B	0%
1 Feb 2023	$2.8B	$1.1B – $3.2B	$2.8B (0%)	after a round	3,700	unknown	B	0%
1 Mar 2023	$2.8B	$1.1B – $3.2B	$2.8B (0%)	after a round	3,700	unknown	B	0%
1 Apr 2023	$2.8B	$1.1B – $3.2B	$2.8B (0%)	after a round	3,700	unknown	B	0%
1 May 2023	$2.8B	$981M – $3.2B	$2.8B (0%)	after a round	3,700	unknown	B	0%
1 Jun 2023	$2.8B	$932M – $3.2B	$2.8B (0%)	after a round	3,700	unknown	C	0%
1 Jul 2023	$2.8B	$888M – $3.2B	$2.8B (0%)	after a round	3,700	unknown	C	0%
1 Aug 2023	$2.8B	$844M – $3.2B	$2.8B (0%)	after a round	3,700	unknown	C	0%
1 Sep 2023	$2.8B	$802M – $3.2B	$2.8B (0%)	after a round	3,700	unknown	C	0%
1 Oct 2023	$2.8B	$763M – $3.2B	$2.8B (0%)	after a round	3,700	unknown	C	0%
1 Nov 2023	$2.8B	$725M – $3.2B	$2.6B (-6%)	after a round	3,700	flat	C	0%
1 Dec 2023	$2.8B	$690M – $3.2B	$2.6B (-6%)	after a round	3,700	flat	C	0%
1 Jan 2024	$2.8B	$656M – $3.2B	$2.6B (-7%)	after a round	3,700	flat	C	0%
1 Feb 2024	$2.8B	$623M – $3.2B	$2.6B (-8%)	after a round	3,700	flat	C	0%
1 Mar 2024	$2.8B	$594M – $3.2B	$2.5B (-9%)	after a round	3,700	flat	C	0%
1 Apr 2024	$2.5B	$562M – $3.2B	$2.1B (-14%)	after a round	3,600	flat	C	12%
1 May 2024	$710M	$617M – $888M	$772M (+9%)	after a round	3,600	flat	A	12%
1 Jun 2024	$715M	$617M – $888M	$769M (+8%)	after a round	3,600	flat	A	12%
1 Jul 2024	$720M	$617M – $888M	$766M (+6%)	after a round	3,600	flat	A	12%
1 Aug 2024	$725M	$617M – $887M	$761M (+5%)	after a round	3,600	flat	A	14%
1 Sep 2024	$732M	$617M – $892M	$764M (+4%)	after a round	3,700	flat	A	13%
1 Oct 2024	$737M	$617M – $893M	$763M (+4%)	after a round	3,700	flat	A	12%
1 Nov 2024	$743M	$617M – $894M	$763M (+3%)	after a round	3,700	flat	A	11%
1 Dec 2024	$749M	$617M – $895M	$762M (+2%)	after a round	3,700	flat	A	10%
1 Jan 2025	$755M	$617M – $896M	$762M (+1%)	after a round	3,700	flat	A	9%
1 Feb 2025	$762M	$617M – $896M	$762M (0%)	after a round	3,700	flat	A	8%
1 Mar 2025	$768M	$617M – $897M	$762M (-1%)	after a round	3,700	flat	A	8%
1 Apr 2025	$774M	$617M – $897M	$763M (-2%)	after a round	3,700	flat	A	7%
1 May 2025	$781M	$616M – $898M	$761M (-2%)	after a round	3,700	flat	A	6%
1 Jun 2025	$780M	$586M – $899M	$762M (-2%)	after a round	3,700	flat	A	6%
1 Jul 2025	$779M	$558M – $899M	$762M (-2%)	after a round	3,700	flat	A	5%
1 Aug 2025	$788M	$533M – $912M	$773M (-2%)	after a round	3,935	flat	A	5%
1 Sep 2025	$788M	$507M – $912M	$774M (-2%)	after a round	3,934	flat	A	5%
1 Oct 2025	$788M	$483M – $913M	$774M (-2%)	after a round	3,932	flat	B	4%
1 Nov 2025	$787M	$460M – $913M	$775M (-2%)	after a round	3,932	flat	B	4%
1 Dec 2025	$787M	$439M – $913M	$776M (-1%)	after a round	3,930	flat	B	4%
1 Jan 2026	$787M	$418M – $914M	$777M (-1%)	after a round	3,930	flat	B	3%
1 Feb 2026	$788M	$398M – $915M	$778M (-1%)	after a round	3,940	flat	B	3%
1 Mar 2026	$788M	$380M – $915M	$779M (-1%)	after a round	3,940	flat	B	3%
1 Apr 2026	$789M	$363M – $916M	$780M (-1%)	after a round	3,963	flat	B	3%
1 May 2026	$788M	$346M – $917M	$779M (-1%)	after a round	3,963	flat	B	2%
1 Jun 2026	$789M	$329M – $917M	$774M (-2%)	after a round	3,974	flat	B	2%
1 Jul 2026	$789M	$313M – $917M	$769M (-3%)	after a round	3,974	flat	B	2%
1 Aug 2026	$789M	$297M – $917M	$763M (-3%)	after a round	3,962	flat	B	2%
1 Sep 2026	$798M	$283M – $918M	$773M (-3%)	after a round	3,977	flat	B	0%
1 Oct 2026	$798M	$269M – $918M	$767M (-4%)	after a round	3,978	flat	C	0%
24 Oct 2026	$810M	$259M – $932M	$791M (-2%)	after a round	3,978	flat	C	0%

Key facts about PharmEasy

Founded: 2015
Headquarters: Mumbai, India
Employees: about 3,980 +1% in a year
Total raised: $1.06B
Funding rounds: 8
Last round: Debt Sep 2025

PharmEasy was founded in 2015 by Dharmil Sheth, Dhaval Shah, Hardik Dedhia, Harsh Parekh and Siddharth Shah.

PharmEasy funding history

PharmEasy has 8 funding rounds on record, from Jan 2016 to Sep 2025, $1.06B in total. The latest disclosed valuation is $710M post-money (Growth Equity, Apr 2024).

Debt 1 Sep 2025no round page
Led by 360 One; with Micro Labs Limited, MVS Ventures, Bennett Coleman, Alkram Ventures, Kyrush Investments, Medley Pharmaceuticals, Mahalaxmi Trust.
Sources: healthcare.digital, entrackr.com, indianstartupnews.com and 2 more
$193M
Growth Equity 30 Apr 2024
Led by Manipal Education and Medical Group; with Prosus, Temasek, 360 One Portfolios, La Caisse, WSSS Investments, Goldman Sachs, EvolutionX Debt Capital.
Sources: healthcare.digital, entrackr.com, yourstory.com and 3 more
$216M
$710M post-money, below the round before
Series E 7 Apr 2021
Led by Prosus Ventures, TPG; with Temasek, La Caisse, Lightrock, Eight Roads, Think Investments.
Sources: gunder.com, entrackr.com, yourstory.com and 2 more
$350M
$1.50B post-money
Growth Equity 27 Nov 2019
Investors not disclosed.
Sources: startupnewsasia.com, entrackr.com
$220M
Debt 27 Sep 2018no round page
With InnoVen Capital.
Sources: medianama.com
$5.5M
Series C 26 Sep 2018
Led by Eight Roads; with F-Prime Capital, Fundamentum, Think Investments, Bessemer Venture Partners, Fidelity International Ltd.
Sources: medianama.com, medianama.com, yourstory.com
$50M
Series B 3 Apr 2017
Led by Bessemer Venture Partners, Orios Venture Partners; with Aarin Capital.
Sources: finsmes.com, yourstory.com, medianama.com and 1 more
$17M
Series A 1 Jan 2016
Led by Bessemer Venture Partners; with Orios Venture Partners.
Sources: medianama.com
$5.0M

PharmEasy investors

28 investors have backed PharmEasy; Bessemer Venture Partners, Eight Roads and Orios Venture Partners and 4 more led at least one round.

Bessemer Venture Partners lead, 3 rounds
360 One lead
Manipal Education and Medical Group lead
Prosus Ventures lead
TPG lead
La Caisse 2 rounds
Temasek 2 rounds
360 One Portfolios
Alkram Ventures
Bennett Coleman
Fidelity International Ltd
Goldman Sachs
Kyrush Investments
Lightrock
Mahalaxmi Trust
Medley Pharmaceuticals
Micro Labs Limited
MVS Ventures
Prosus
WSSS Investments

What PharmEasy does

PharmEasy works in drug stores & pharmacies, with 14 recorded offerings and customers in healthcare.

Axelia Solutions Private Limited, known as PharmEasy, is an Indian private company operating as an e-commerce platform and digital healthcare aggregator. The company provides prescription and over-the-counter medicines, healthcare products, diagnostic tests, and teleconsultations through its digital platform. PharmEasy also offers home delivery of healthcare products and diagnostic services, and operates a supply chain and logistics network to support its operations. The company is certified as a Great Place to Work.

Description from Veridion's company data.

Products and services

Digital Healthcare Platform Services
Prescription and Over-the-Counter Medicine Retail
Diagnostic Test Services
Teleconsultation Services
Healthcare Product Retail
Personal Care Product Retail
Vitamins and Supplements Retail
Healthcare Device Retail
Express Medicine Delivery Services
Phlebotomy Services for Diagnostic Tests
Automated Sample Processing Services
Digital Diagnostic Reporting Services
COVID-19 RT-PCR Test Services
Home-Delivered Healthcare Product Services

Markets

Healthcare

Technology

Automated Sample Processing and Digital Reporting

Supply chain

Direct-to-Consumer Distribution

Business model

Business-to-Consumer
Service Provider
Retail
E-commerce
On-Demand

Industry codes (NAICS)

456110 Pharmacies and Drug Retailers 70% match
621511 Medical Laboratories 30% match

Questions about PharmEasy

What is PharmEasy worth?

Valuation $810M (range $259M to $932M), as of 24 Oct 2026. The last disclosed valuation was $710M (Growth Equity, Apr 2024).

Has PharmEasy raised money?

PharmEasy has 8 funding rounds on record, from Jan 2016 to Sep 2025, $1.06B in total. The latest disclosed valuation is $710M post-money (Growth Equity, Apr 2024).

Who has invested in PharmEasy?

Bessemer Venture Partners, Eight Roads, Orios Venture Partners, 360 One, Manipal Education and Medical Group and Prosus Ventures, and 22 more. Lead investors include Bessemer Venture Partners, Eight Roads, Orios Venture Partners and 360 One.

How many people work at PharmEasy?

About 3,980, up 1% over the last year. Headcount grew from 740 in Jan 2021 to 3,978 in Sep 2026.

What does PharmEasy do?

PharmEasy works in drug stores & pharmacies, with 14 recorded offerings and customers in healthcare. Its main offerings are digital healthcare platform services, prescription and over-the-counter medicine retail and diagnostic test services.

When was PharmEasy founded, and where is it based?

PharmEasy was founded in 2015 and is based in Mumbai, India. It has about 3,980 employees, up 1% over the last year.

How we value companies Report an issue

PharmEasy valuation, funding and investors

PharmEasy valuation today

Key facts about PharmEasy

PharmEasy funding history

Debt 1 Sep 2025no round page

Growth Equity 30 Apr 2024

Series E 7 Apr 2021

Growth Equity 27 Nov 2019

Debt 27 Sep 2018no round page

Series C 26 Sep 2018

Series B 3 Apr 2017

Series A 1 Jan 2016